One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
doi : 10.1111/dom.15892
Sodium-glucose co-transporter-2 inhibitors: Writing the next chapter of a unique success story
doi : 10.1111/dom.15909
Copper homeostasis and cuproptosis-related genes: Therapeutic perspectives in non-alcoholic fatty liver disease
doi : 10.1111/dom.15846
Generating real-world evidence on diabetes technology using the CareLink Personal data management system
doi : 10.1111/dom.15868
The effectiveness and sustainability of health outcomes from a holistic digital weight-loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK
doi : 10.1111/dom.15903
Degree of joint risk factor control and incident chronic kidney disease among individuals with obesity
doi : 10.1111/dom.15874
A cohort analysis of familial partial lipodystrophy from two Mediterranean countries
doi : 10.1111/dom.15882
The association of type 2 diabetes-related characteristics with fracture risk at different sites
doi : 10.1111/dom.15884
Health-related quality of life of people with type 1 diabetes: An IMI2 SOPHIA post hoc analysis of FUTURE and ADJUNCT-ONE
doi : 10.1111/dom.15886
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial
doi : 10.1111/dom.15889
Performance of the MiniMed 780G system on mitigating menstrual cycle-dependent glycaemic variability
doi : 10.1111/dom.15891
Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023
doi : 10.1111/dom.15893
Prognostic value of the stress-hyperglycaemia ratio in patients with moderate-to-severe coronary artery calcification: Insights from a large cohort study
doi : 10.1111/dom.15894
[P3]PP, a stable, long-acting pancreatic polypeptide analogue, evokes weight lowering and pancreatic beta-cell-protective effects in obesity-associated diabetes
doi : 10.1111/dom.15897
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study
doi : 10.1111/dom.15898
Glucose-lowering medicines use before and after entry into long-term care facilities
doi : 10.1111/dom.15905
Birthweight influences liver structure, function and disease risk: Evidence of a causal association
doi : 10.1111/dom.15910
Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program
doi : 10.1111/dom.15911
Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies
doi : 10.1111/dom.15912
Prevalence of complications and co-morbidities in males and females with obesity: Real-world insights from claims data analysis
doi : 10.1111/dom.15914
Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial
doi : 10.1111/dom.15915
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
doi : 10.1111/dom.15768
Variations in healthcare costs by body mass index and obesity-related complications in a UK population: A retrospective open cohort study
doi : 10.1111/dom.15785
Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials
doi : 10.1111/dom.15811
Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: A retrospective open cohort study
doi : 10.1111/dom.15836
Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
doi : 10.1111/dom.15838
Safety evaluation of bi-layered allogenic keratinocyte and fibroblast skin substitute for diabetic foot ulcers—SAFESKIN-DFU: A Phase 1 clinical trial
doi : 10.1111/dom.15843
Independent and joint relationships of cardiorespiratory fitness and body mass index with liver fat content
doi : 10.1111/dom.15847
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was
doi : 10.1111/dom.15851
Bidirectional association between type 2 diabetes and irritable bowel syndrome: A large-scale prospective cohort study
doi : 10.1111/dom.15852
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease
doi : 10.1111/dom.15853
Association of Life's Essential 8 with abdominal aortic calcification and mortality among middle-aged and older individuals
doi : 10.1111/dom.15854
Trajectory of haemoglobin A1c and incidence of cardiovascular disease in patients with type 2 diabetes mellitus
doi : 10.1111/dom.15856
Sweetened beverages and atrial fibrillation in people with prediabetes or diabetes
doi : 10.1111/dom.15859
Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
doi : 10.1111/dom.15860
Glycated haemoglobin variability and risk of renal function decline in type 2 diabetes mellitus: An updated systematic review and meta-analysis
doi : 10.1111/dom.15861
Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
doi : 10.1111/dom.15864
Association of glycaemic control with intraocular pressure in a large general population: Results from the UK Biobank
doi : 10.1111/dom.15865
Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis
doi : 10.1111/dom.15866
Ethnic differences in the relationship between ectopic fat deposition and insulin sensitivity in Black African and White European men across a spectrum of glucose tolerance
doi : 10.1111/dom.15867
Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
doi : 10.1111/dom.15869
The effectiveness of telemonitoring and integrated personalized diabetes management in people with insulin-treated type 2 diabetes mellitus
doi : 10.1111/dom.15870
Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
doi : 10.1111/dom.15872
Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population
doi : 10.1111/dom.15878
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
doi : 10.1111/dom.15879
Fish oil supplementation in relation to the risk of chronic kidney disease among patients with diabetes
doi : 10.1111/dom.15880
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double-blind, placebo-controlled trial
doi : 10.1111/dom.15881
Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies
doi : 10.1111/dom.15887
Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
doi : 10.1111/dom.15888
Fracture risk revisited: Bone mineral density T-score and fracture risk in type 2 diabetes
doi : 10.1111/dom.15890
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
doi : 10.1111/dom.15895
Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes
doi : 10.1111/dom.15896
Optimizing physician-encounter frequency for type 2 diabetes patients in primary care based on cardiovascular risk assessment: A target trial emulation study
doi : 10.1111/dom.15899
Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: Up to 40 months’ follow-up
doi : 10.1111/dom.15900
A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations
doi : 10.1111/dom.15901
Reduced insulin clearance in paediatric metabolic (dysfunction)-associated fatty liver disease and its dual role in beta-cell offload and diabetes risk
doi : 10.1111/dom.15902
Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan
doi : 10.1111/dom.15908
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study
doi : 10.1111/dom.15917
Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks
doi : 10.1111/dom.15918
Ultra-processed foods cause weight gain and increased energy intake associated with reduced chewing frequency: A randomized, open-label, crossover study
doi : 10.1111/dom.15922
Mediating role of inflammatory biomarkers in the causal effect of body composition on glycaemic traits and type 2 diabetes
doi : 10.1111/dom.15923
The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021
doi : 10.1111/dom.15924
The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study
doi : 10.1111/dom.15862
Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost-effectiveness analysis
doi : 10.1111/dom.15873
A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy
doi : 10.1111/dom.15875
Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study
doi : 10.1111/dom.15876
Use of real-time continuous glucose monitoring in non-critical care insulin-treated inpatients under non-diabetes speciality teams in hospital: A pilot randomized controlled study
doi : 10.1111/dom.15885
Immune checkpoint inhibitor-induced diabetes: Twists and turns of diabetology
doi : 10.1111/dom.15848
The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial
doi : 10.1111/dom.15857
